Cargando…

Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease

Chronic kidney disease is one of the leading causes of morbidity and mortality in the Philippines. It is associated with a growing health burden as many patients progress to end-stage renal disease. Until recently, therapeutic options for the management of chronic kidney disease were limited. Sodium...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isidto, Rey, Danguilan, Romina, Naidas, Oscar, Vilanueva, Russell, Arakama, Mel-Hatra, Paraiso, Layla Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960786/ https://www.ncbi.nlm.nih.gov/pubmed/36852177 http://dx.doi.org/10.2147/IJNRD.S387262

Ejemplares similares

Incidence of, and Risk Factors and Outcomes Associated with, Acute Kidney Injury in COVID-19 at the National Kidney and Transplant Institute, Philippines
por: Altillero, Melchor, et al.
Publicado: (2023)

Comparison of Outcomes among Chronic Kidney Disease V Patients with COVID-19 at the National Kidney and Transplant Institute: A Retrospective Cohort Study
por: Bautista, Maria Fe, et al.
Publicado: (2022)

A Scoring Tool to Predict Pulmonary Complications in Severe Leptospirosis with Kidney Failure
por: So, Rizza Antoinette Yap, et al.
Publicado: (2022)

Clinical characteristics, outcomes, and management of COVID-19 in kidney transplant recipients across Asia: an ASTREGO report
por: Kee, Terence, et al.
Publicado: (2021)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
por: Zanoli, L., et al.
Publicado: (2015)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

Sodium‐glucose co‐transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction
por: Tiwary, Mansi, et al.
Publicado: (2022)

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
por: Chan, Anthony T. P., et al.
Publicado: (2022)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
por: Neumiller, Joshua J, et al.
Publicado: (2022)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan
por: Chung, Mu-Chi, et al.
Publicado: (2023)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow
por: Kelwade, Jayant, et al.
Publicado: (2014)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015)

Sodium glucose co-transporter inhibitors – A new class of old drugs
por: Malhotra, Aneeta, et al.
Publicado: (2015)

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
por: Seo, Ji A
Publicado: (2018)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers
por: Ali, Kabeer, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
por: Wojtas, Caroline, et al.
Publicado: (2023)

Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
por: Kourtidou, Christodoula, et al.
Publicado: (2023)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
por: Bays, Harold
Publicado: (2013)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o6re9hm90nfmc0v6dtcf27l7ap